Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with ...

Shown is the probability of a best response to step-up therapy with a long-acting beta-agonist (LABA), an inhaled corticosteroid (ICS), or a leukotriene-receptor antagonist (LTRA), according to ...

Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better outcomes” than an inhaled corticosteroid plus LABA. This result was sustained in ...

rescue inhaler to next-generation SMART meds that combine an inhaled corticosteroid with a long-acting bronchodilator (LABA). The medications inside inhalers work in different ways and are ...

According to 2015 gross cost data supplied by the insurer, the average cost per inhaler regimen consisting of an ICS/LABA inhaler ($298) and a LAMA inhaler ($310) was $608 compared with $493 for a ...

In a secondary analysis of serious asthma-related events, 0.6% of 18,006 patients in the inhaled-glucocorticoid group and 0.66% of 18,004 patients in the combination-therapy group had at last 1 ...

Keep formoterol out of the reach of children. Formoterol is a long-acting beta2-agonist (LABA). Do not use formoterol with other inhaled medicines that contain a LABA. Make sure that you ...

an inhaled corticosteroid (ICS); glycopyrrolate, a long-acting muscarinic antagonist; and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA). The replicate, randomized, double ...